Erythropoietin receptor antagonist suppressed ectopic hemoglobin synthesis in xenografts of HeLa cells to promote their destruction

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Yasuda, Yoshiko ^a   Fujita, Mitsugu ^a   Koike, Eiji ^a   Obata, Koshiro ^b   Shiota, Mitsuru ^c   Kotani, Yasushi ^a   Musha, Terunaga ^d   Tsuji Kawahara, Sachiyo ^a   Satou, Takao ^a   Masuda, Seiji ^e   Okano, Junko ^f   Yamasaki, Harufumi ^a   Okumoto, Katsumi ^a   Uesugi, Tadao ^a   Nakao, Shinichi ^a   Hoshiai, Hiroshi ^a   Mandai, Masaki ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d Department of Gynecology Medicalcourt Hachinohe West Hospital   (Japan)

^e KYOTO UNIVERSITY   (Japan)

^f SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN MIMETIC PEPTIDE 9; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; HEMOGLOBIN ALPHA CHAIN; HEMOGLOBIN EPSILON CHAIN; HEMOGLOBIN GAMMA CHAIN; HORMONE RECEPTOR BLOCKING AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; MYOGLOBIN; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PEPTIDOMIMETIC AGENT; PROTEIN KINASE B; STAT5 PROTEIN; UNCLASSIFIED DRUG; ERYTHROPOIETIN; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL SURFACE; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; HEMOGLOBIN SYNTHESIS; IN VIVO STUDY; INNATE IMMUNITY; MACROPHAGE; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL DESTRUCTION; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; EXPERIMENTAL NEOPLASM; GENE EXPRESSION; GENETICS; HELA CELL LINE; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNTHESIS; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; ERYTHROPOIETIN; GENE EXPRESSION; HELA CELLS; HEMOGLOBINS; HETEROGRAFTS; HUMANS; MALE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS, EXPERIMENTAL; PEPTIDES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ERYTHROPOIETIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TRANSPLANTATION, HETEROLOGOUS;

EID: 84928776340     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122458     Document Type: Article

References (54)

1. Krantz SB. Erythropoietin. Blood. 1991; 77:419-434. PMID: 1991159
2. Nijhof W, Wierenga PK, Sahr K, Beru N, Goldwasser E. Induction of globin mRNA transcription by erythropoietin in differentiating erythroid precursor cells. Exp Hematol. 1987; 15:779-784. PMID: 3609181
3. Katsumura KR, DeVilbiss AW, Pope NJ, Johnson KD, Bresnick EH. Transcriptional mechanisms underlying hemoglobin synthesis. Cold Spring Harb Perspect Med. 2013; 3:a015412. doi: 10.1101/cshperspect.a015412 PMID: 23838521
4. Yasuda Y, Sasaki T, Takagawa M, Maeda M, Yasuda M, Atsumi T, et al. Erythropoietin contributes to implantation: ectopic hemoglobin synthesis in decidual cells of mice. Congenit Anom (Kyoto). 2007; 47:22-33. PMID: 17300687
5. Shiota M, Yasuda Y, Shimaoka M, Tsuritani M, Koike E, Oiki M, et al. Erythropoietin is involved in hemoprotein syntheses in developing human decidua. Congenit Anom (Kyoto). 2013; 53:18-26. doi: 10.1111/j.1741-4520.2012.00382.x PMID: 23480354
6. Yasuda Y, Musha T, Tanaka H, Fujita Y, Fujita H, Utsumi H, et al. Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer. 2001; 84:836-843. PMID: 11259101
7. Yasuda Y, Fujita Y, Musha T, Tanaka H, Shiokawa S, Nakamatsu K, et al. Expression of erythropoietin in human female reproductive organs. Ital J Anat Embryol. 2001; 106:215-222. PMID: 11767197
8. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003; 4:459-460. PMID: 12901958
9. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003; 362:1255-1260. PMID: 14575968
10. Henke M, Mattern D, Pepe M, Bezay C, Weissenberger C, Werner M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol. 2006; 24:4708-4713. PMID: 17028293
11. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003; 102:1340-1346. PMID: 12702503
12. Hardee ME, Cao Y, Fu P, Jiang X, Zhao Y, Rabbani ZN, et al. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS One. 2007; 2:e549. PMID: 17579721
13. Yasuda Y, Fujita Y, Masuda S, Musha T, Ueda K, Tanaka H, et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis. 2002; 23:1797-1805. PMID: 12419827
14. Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis. 2003; 24:1021-1029. PMID: 12807756
15. Johnson DL, Farrell FX, Barbone FP, McMahon FJ, Tullai J, Hoey K, et al. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. Biochemistry. 1998; 37:3699-3710. PMID: 9521688
16. Lifshitz L, Prutchi-Sagiv S, Avneon M, Gassmann M, Mittelman M, Neumann D. Non-erythroid activities of erythropoietin: Functional effects on murine dendritic cells. Mol Immunol. 2009; 46:713-721. doi: 10.1016/j.molimm.2008.10.004 PMID: 19027957
17. Lifshitz L, Tabak G, Gassmann M, Mittelman M, Neumann D. Macrophages as novel target cells for erythropoietin. Haematologica. 2010; 95:1823-1831. doi: 10.3324/haematol.2010.025015 PMID: 20595096
18. Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG. The role of nitric oxide in cancer. Cell Res. 2002; 12:311-320. PMID: 12528889
19. Xu WM, Liu LZ. Nitric oxide: from a mysterious labile factor to the molecule of the Nobel Prize. Recent progress in nitric oxide research. Cell Res. 1998; 8:251-258. PMID: 9934533
20. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999; 399:601-605. PMID: 10376603
21. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999; 399:597-601. PMID: 10376602
22. Silva CS, Michelin MA, Etchebehere RM, Adad SJ, Murta EF. Local lymphocytes and nitric oxide synthase in the uterine cervical stroma of patients with grade III cervical intraepithelial neoplasia. Clinics (Sao Paulo). 2010; 65:575-581. doi: 10.1590/S1807-59322010000600003 PMID: 20613932
23. Eggen T, Sager G, Arnes M, Pettersen I, Orbo A. Expression of iNOS - a favourable prognostic marker for early-stage carcinoma of the uterine cervix. Anticancer Res. 2011; 31:2319-2325. PMID: 21737658
24. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90. doi: 10.3322/caac.20107 PMID: 21296855
25. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010; 10:550-560. doi: 10.1038/nrc2886 PMID: 20592731
26. Mantovani F, Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene. 2001; 20:7874-7887. PMID: 11753670
27. Gadducci A, Tana R, Cosio S, Cionini L. Treatment options in recurrent cervical cancer (Review). Oncol Lett. 2010; 1:3-11. PMID: 22966247
28. Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005; 23:4626-4633. PMID: 15911865
29. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009; 27:4649-4655. doi: 10.1200/JCO.2009.21.8909 PMID: 19720909
30. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2:38-47. PMID: 11902584
31. Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol. 2003; 162:1789-1806. PMID: 12759237
32. Shenouda G, Mehio A, Souhami L, Duclos M, Portelance L, Belenkov A, et al. Erythropoietin receptor expression in biopsy specimens from patients with uterine cervix squamous cell carcinoma. Int J Gynecol Cancer. 2006; 16:752-756. PMID: 16681756
33. Leo C, Horn LC, Rauscher C, Hentschel B, Liebmann A, Hildebrandt G, et al. Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis. Clin Cancer Res. 2006; 12:6894-6900. PMID: 17145806
34. Lopez TV, Lappin TR, Maxwell P, Shi Z, Lopez-Marure R, Aguilar C, et al. Autocrine/paracrine erythropoietin signalling promotes JAK/STAT-dependent proliferation of human cervical cancer cells. Int J Cancer. 2011; 129:2566-2576. doi: 10.1002/ijc.25935 PMID: 21442620
35. Yasuda M, Matsubara J, Yamasaki H, Fujita Y, Konishi H, Koinuma S, et al. Death-resistant and nonresistant malignant human cell lines under anoxia in vitro. Int J Clin Oncol. 2007; 12:455-462. PMID: 18071865
36. Yasuda Y, Maeda Y, Hara S, Tanaka M, Koike E, Watanabe Y, et al. Constitutively active soluble form of erythropoietin receptor suppresses growth and angiogenesis of xenografts of transfected cancer cell lines J Canc Ther. 2011; 2:40-53.
37. Yasuda Y, Maeda Y, Koike E, Watanabe Y, Masuda S, Yamasaki H, et al. Cancer cell lines' growth is promoted through individual responsiveness to autocrine and/or exogenous erythropoietin in vitro. WSEAS Press. Cambridge. 2010;: 337-348.
38. Ohba N, Kiryu-Seo S, Maeda M, Muraoka M, Ishii M, Kiyama H. Transgenic mouse overexpressing the Akt reduced the volume of infarct area after middle cerebral artery occlusion. Neurosci Lett. 2004; 359:159-162. PMID: 15050688
39. Yasuda Y, Nagao M, Okano M, Masuda S, Sasaki R, Konishi H, et al. Localization of erythropoietin and erythropoietin-receptor in postimplantation mouse embryos. Develop Growth Differ. 1993; 35: 711-722.
40. Yasuda Y, Hara S, Hirohata T, Koike E, Yamasaki H, Okumoto K, et al. Erythropoietin-responsive sites in normal and malignant human lung tissues. Anat Sci Int. 2010; 85:204-213. doi: 10.1007/s12565-010-0081-7 PMID: 20397063
41. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996; 86:147-157. PMID: 8689682
42. Li F, Srinivasan A, Wang Y, Armstrong RC, Tomaselli KJ, Fritz LC. Cell-specific induction of apoptosis by microinjection of cytochrome c. Bcl-xL has activity independent of cytochrome c release. J Biol Chem. 1997; 272:30299-30305. PMID: 9374516
43. Nishio N, Fujita M, Tanaka Y, Maki H, Zhang R, Hirosawa T, et al. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysismediated by human gammadelta T cells. J Immunother. 2012; 35:598-606. PMID: 22996365
44. Cheung JY, Zhang XQ, Bokvist K, Tillotson DL, Miller BA. Modulation of calcium channels in human erythroblasts by erythropoietin. Blood. 1997; 89:92-100. PMID: 8978281
45. Miller BA, Barber DL, Bell LL, Beattie BK, Zhang MY, Neel BG, et al. Identification of the erythropoietin receptor domain required for calcium channel activation. J Biol Chem. 1999; 274:20465-20472. PMID: 10400674
46. Jaconi ME, Lew DP, Carpentier JL, Magnusson KE, Sjogren M, Stendahl O. Cytosolic free calcium elevation mediates the phagosome-lysosome fusion during phagocytosis in human neutrophils. J Cell Biol. 1990; 110:1555-1564. PMID: 2110568
47. Flonta SE, Arena S, Pisacane A, Michieli P, Bardelli A. Expression and functional regulation of myoglobin in epithelial cancers. Am J Pathol. 2009; 175:201-206. doi: 10.2353/ajpath.2009.081124 PMID: 19541931
48. Gorr TA, Wichmann D, Pilarsky C, Theurillat JP, Fabrizius A, Laufs T, et al. Old proteins - new locations: myoglobin, haemoglobin, neuroglobin and cytoglobin in solid tumours and cancer cells. Acta Physiol (Oxf). 2011; 202:563-581. doi: 10.1111/j.1748-1716.2010.02205.x PMID: 20958924
49. Wunderlich C, Flogel U, Godecke A, Heger J, Schrader J. Acute inhibition of myoglobin impairs contractility and energy state of iNOS-overexpressing hearts. Circ Res. 2003; 92:1352-1358. PMID: 12775582
50. Brunori M. Nitric oxide moves myoglobin centre stage. Trends Biochem Sci. 2001; 26:209-210. PMID: 11295538
51. Fraser J, de Mello LV, Ward D, Rees HH, Williams DR, Fang Y, et al. Hypoxia-inducible myoglobin expression in nonmuscle tissues. Proc Natl Acad Sci U S A. 2006; 103:2977-2981. PMID: 16469844
52. Brookes M, Zietman A. Clinical Embryology: a Color Atlas and Text. CRC Press LLC. Florida. 1998;: 142.
53. Blackwell KL, Kirkpatrick JP, Snyder SA, Broadwater G, Farrell F, Jolliffe L, et al. Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin. Cancer Res. 2003; 63:6162-6165. PMID: 14559797
54. Moore MA. Stem cell proliferation: ex vivo and in vivo observations. Stem Cells 15 Suppl. 1997; 1:239-248. PMID: 9368348